Heidi Nelson named medical director of the American College of Surgeons Cancer Programs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Heidi Nelson, a colorectal surgeon from Mayo Clinic, was named medical director of Cancer Programs in the American College of Surgeons Division of Research and Optimal Patient Care.

Nelson succeeds David Winchester as he transitions from the position he has served in for more than 30 years. Nelson comes to the ACS from her position as chair, and vice chair for research, of the department of surgery, Mayo Clinic, as well as professor of surgery, Mayo Clinic College of Medicine and Sciences, Rochester, Minn. She has master’s faculty privileges in clinical and translation science at the Mayo Clinic Graduate School of Biomedical Sciences and the Mayo Clinic College of Medicine and Science.

As the Fred C. Andersen Professor for the Mayo Foundation and a consultant for Mayo Clinic’s division of colon and rectal surgery, Nelson is internationally renowned for her research in the field of colon and rectal cancer.

Nelson’s work has also helped reduce the cancer burden in patients with locally advanced and recurrent rectal cancer through studies examining the role of complex surgeries and intraoperative radiation therapy. Nelson will be starting at the ACS later this month.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login